Previous close | 0.8450 |
Open | 0.8450 |
Bid | 0.8150 x 853200 |
Ask | 0.8500 x 1877300 |
Day's range | 0.8150 - 0.8500 |
52-week range | 0.7950 - 1.9800 |
Volume | |
Avg. volume | 110,512 |
Market cap | 171.432M |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0670 |
Earnings date | 22 Feb 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.65 |
JACKSONVILLE, Fla., May 10, 2022--Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, "A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty," also found that XPERIENCE produced minima
Every investor in Next Science Limited ( ASX:NXS ) should be aware of the most powerful shareholder groups. Insiders...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...